This clinical trial is focused on studying the effectiveness and safety of a medication called Rimegepant for treating migraine attacks in adults who cannot use another type of medication known as triptans. Migraines are severe headaches that can occur with or without warning signs, known as aura, and can last from a few hours to several days if untreated. The study aims to compare how well Rimegepant works in relieving migraine pain compared to a placebo.

Participants in the study will be randomly assigned to receive either Rimegepant or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The main goal is to see if Rimegepant can reduce the intensity of migraine pain within two hours after taking the medication. The study will also look at other factors, such as whether participants need additional medication within 24 hours and how the medication affects their ability to function normally during a migraine attack.

The trial will take place over a period of time, and participants will be monitored to assess the medication’s impact on their migraine symptoms. The study will help determine if Rimegepant is a suitable option for those who cannot use triptans, providing valuable information on its potential benefits and any side effects. The results will contribute to understanding how Rimegepant can be used in managing migraines effectively.